Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Phase 1 Terminated 66 enrolled Oncorus, Inc. Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Timeline

Start: 2020-05-20
Primary completion: 2023-05-31
Completion: 2023-05-31

Outcome

Outcome not reported

Stopped (Business): “Terminated due to Oncorus portfolio reprioritization”

Publications

Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, Wambua D, Kong L, Behera P, Jacques J, Goshert C, Ball M, Colthart A, Finer MH, Hayes MW, Feau S, Kennedy EM, Lerner L, Queva C. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity. Cancer Immunol Res. 2021 Mar;9(3):291-308. doi: 10.1158/2326-6066.CIR-20-0609. Epub 2020 Dec 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ONCR-177	Unknown	—	Other
Subject	Pembrolizumab	Monoclonal antibody	—	—